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During the last decade, the development of several potentially
potent anti-viral agents against hepatitis B virus (HBV) infection
was discontinued for a variety of reasons. Among them was
Clevudine, a drug which interferes in a number of steps in the
HBV replication cycle. Clevudine distinguished itself due to sev-
eral attractive properties including its sustained suppression of
circulating HBV-DNA observed after 24 weeks of treatment dis-
continuation as well as a reduction in intrahepatic cccDNA.
Despite these properties, phase III studies came to a halt in most
countries due to initially anecdotal reports of Clevudine associ-
ated myopathy and fear of mitochondrial toxicity as well as early
selection of an rt181T mutation also observed in resistance to
lamivudine and adefovir. Yet, following the successful comple-
tion of a 24 week placebo controlled trial in HBeAg positive and
negative HBV patients, Korea, remained the only country in
which Clevudine was licensed for chronic HBV infection (CHB).
Since 2009, more than 10 reports from Korea appeared in the lit-
erature describing various aspects of Clevudine associated
myopathy.
In this issue of the Journal, Dr. Tak and co-workers report their
experience in 363 CHB patients treated with Clevudine, 30 mg/
day for more than 24 weeks and closely followed prospectively
for a mean period of 18.0 months (9–24) for the clinical signs
of myopathy and neuropathy. The diagnosis of myopathy was
established in 10% of the patients and was mainly based on clin-
ical signs of lower limb proximal muscle weakness, elevated
muscle enzymes, and in the majority of cases a muscle biopsy
was also taken. Evidence for myopathy was supported by electro-
physiologic studies and elevated lactic acid levels. Fortunately,
symptoms and signs of myopathy were reversible in all patients
within 2–9 months following cessation of Clevudine. Statistical
analysis was not provided but the investigators were unable to
identify distinct risk factors or ﬁndings in patients with myopa-
thy as compared to those without. Although the presented data
are not new, this study, conducted in a relatively large cohort
of prospectively followed patients, provides solid clinical infor-
mation which should be useful to clinicians treating patients with
anti-viral agents with potential mitochondrial toxicity. The rela-
tively high incidence of myopathy identiﬁed after the completion
of the licensure trials, strengthens the importance of post licen-
sure surveillance despite initial satisfactory safety results in
phase III clinical evaluations of anti-viral agents. The exact mech-Journal of Hepatology 20
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dine remains unknown. In the discussion, the authors make an
interesting comparison between Clevudine associated myopathy
and Telbivudine induced neuropathy. Finally, in view of the
plethora of new and potent anti-viral agents against HBV that
thus far display a better safety record, there is little justiﬁcation
for continuous use of Clevudine which, apparently, is limited to
Korea only.Albumin dialysis for intractable pruritus
The controversy regarding the use of molecular adsorbent recir-
culating system (MARS) in patients with acute or chronic liver
failure, and the impact of treatment by albumin dialysis on sur-
vival is still unresolved. Yet, cumulative experience with this pro-
cedure suggests that some palliation may be achieved in deﬁned
clinical situations.
A number of cholestatic syndromes including primary biliary
cirrhosis, primary sclerosing cholangitis, benign recurrent intra-
hepatic cholestasis, cholestasis of pregnancy, drug induced chole-
stasis, liver associated graft versus host disease (GVHD), and
others may lead to severe pruritus which occasionally is not
relieved by cholestyramine, colestipol, ursodecholic acid, rifampi-
cin, and naloxone.
There are at least 11 case reports describing between 1 and 7
patients with severe pruritus in whom MARS therapy leads to
complete or partial amelioration of symptoms for a limited per-
iod. Yet, large scale studies with a deﬁned protocol have not been
conducted. In view of the promising initial results obtained
through treatment with MARS in a very limited number of
patients, it is important to capture any available experience in
this difﬁcult to treat population who often have a miserable qual-
ity of life which does not necessarily correlate with the severity of
underlying liver disease. In this issue of the Journal, Dr. Pares and
co-workers have summarized the clinical experience gained in
two centers in Spain who successfully treated 19/20 patients
with severe pruritus by albumin dialysis coupled with hemodial-
ysis (HD) or continuous renal replacement therapy (CRRT). Most
patients received two sessions of treatment within 2 days and 5
patients were treated with additional sessions (1–3) within 4–
43 days from initiation. The severity of pruritus before and after
intervention was assessed by two different scoring methods,
namely a visual analogue scale (VAS) and a semiquantitative
scoring system converted later to the VAS. A rapid improvement
in severity of pruritus was documented already after two treat-
ment sessions and the severity score improved in 72% of patients10 vol. 53 j 219–220
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immediately, remaining at 51% at four weeks post-initiation of
treatment. This effect usually lasted for about 4 weeks in about
one half of patients and was accompanied by a transient decrease
in biochemical markers of cholestasis, including bile acid levels
which dropped in 41% of patients immediately after treatment
and this effect was still present after 4 weeks in 37% of patients.
The impact of treatment on long-term survival was variable with
this invasive procedure but no treatment associated serious
adverse events were reported during the observation period.
The study has however a number of limitations, including among
others the somewhat different protocols used by the two partic-
ipating centers, the different pruritus scoring systems, the choice
of the MARS coupled procedures (HD or CRRT), the number and
duration of treatment sessions, the lack of a control group, the
somewhat heterogenous patient population, and the cost. Never-
theless, the information provided through this observational case
series study will be useful in the palliative treatment of patients
with cholestatic syndromes (including GVHD) with intractable
pruritus who did not respond to conventional therapy.Increased incidence of gastrointestinal carcinomas in
PSC patients with a dominant bile duct stenosis: Fact
or co-incidence?
Patients with primary sclerosing cholangitis (PSC) are at
increased risk ranging from 7% to 13% for developing cholangio-
carcinoma (ChC) [1]. In addition, 25–90% of patients with PSC also
have inﬂammatory bowel disease (IBD). The presence of ulcera-
tive colitis is by itself associated with a 14–31% risk of developing
colorectal carcinoma (CrC) at 10 and 20 years of follow-up,
respectively [2]. In recent years, and for some unclear reasons
yet, the incidence of intrahepatic ChC is rising while the rate of
extrahepatic ChC is dropping worldwide [2–4]. It is therefore
important to identify the risk factors which affect these ﬁndings.
Rudolph and co-workers have previously reported a reduced liver
transplantation free survival in a cohort of 97/171 PSC patients
with dominant bile duct stenosis who were followed prospec-
tively for up to 20 years in Germany [5]. In this issue of the Jour-
nal, these investigators analyzed the impact of a dominant bile
duct stenosis in IBD patients in the same cohort of PSC patients,
as well as the incidence of ChC, CrC, and gall bladder carcinoma.
During the follow-up period (up to 20 years), ChC was detected in
6 patients, CrC in 6 patients, and gallbladder carcinoma in 2
patients with PSC with a dominant stricture who also had IBD.
In contrast, none of the PSC/IBD patients without a dominant
stricture developed ChC or gall bladder carcinoma and only one220 Journal of Hepatology 201had CrC. Furthermore, actuarial liver transplantation free survival
at 18 years was only 23% in PSC patients with IBD and a dominant
bile duct stricture as compared to 77.8% in the patients without
IBD who had a dominant bile duct stricture. Interestingly, the
overall prevalence of bile duct carcinoma was relatively low at
only 3%, rising to 6.2% in patients with a dominant bile duct stric-
ture. The investigators conclude that presence of a dominant bile
duct stenosis in PSC patients with IBD is associated with an
increased risk for developing a carcinoma which most probably
contributes to a reduced survival free of liver transplantation.
The results of this study justify a close follow-up of such PSC/
IBD patients with dominant bile duct stenosis and who are at risk
for developing malignant transformation. Yet caution is advised
in the over-interpretation of data for a number of reasons: (i)
The number of patients with ChC, CrC, and gallbladder carcinoma
identiﬁed during the follow-up is relatively small. (ii) It is difﬁcult
to explain why the actuarial liver transplantation free survival at
18 years of follow-up was lower (although not statistically signif-
icant) in those PSC patients without IBD and without a dominant
bile duct stenosis as compared to patients with IBD. (iii) PSC
patients were treated with variable doses of ursodecholic acid
which at least in theory may confound the risk for development
of cancer. (iv) Newer treatment protocols for IBD such as anti-
TNFa introduced during the past decade may affect the risk for
developing a carcinoma.Conﬂicts of interest
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